Eli Lilly in charts: Obesity and diabetes portfolio drives growth in Q3 with Mounjaro +109% and Zepbound +185% Y/Y

Your email address will not be published. Required fields are marked *

Comment *

Name *

Email *

Website

Save my name, email, and website in this browser for the next time I comment.

Δ